抗逆转录病毒疗法治疗艾滋病疗效与安全性的网状Meta分析OA

Objective To compare the efficacy and safety of different antiretroviral therapy regimens.Methods Randomized controlled trialsrelated antiretroviral therapies for acquired immunodeficiency syn-drome were systematically retrieved from domestic and international databases.The Cochrane Risk of Bias Tool was used to assess the quality of the randomized controlled trials.Data analysis was per-formed using Stata 17.0 software,with effect sizes expressed as odds ratios and 95%confidence intervals.Interventions were ranked using the surface under the cumulative ranking curve values.Results A total of 36 randomized controlled trials were included,of which 19 studies were assessed as having moder-ate-to-low risk of bias.Network meta-analysis results showed that regimens based on newer integrase strand transfer inhibitors dem-onstrated significant advantages in both short-term(48-week)and long-term(96-week)antiviral efficacy.At 48 weeks,the tenofovir alafenamide+emtricitabine+dolutegravir and tenofovir alafen-amide+emtricitabine+bictegravir regimens achieved significantly higher viral suppression rates compared to several traditional regi-mens based on non-nucleoside reverse transcriptase inhibitors or earlier protease inhib-itors.At 96 weeks,DTG-based regimens(including tenofovir disoproxil fumarate+emtricitabine+dolutegravir and abacavir+lami-vudine+dolutegravir)showed significantly higher viral suppression rates than traditional regimens and were superior to the 48-week tenofovir alafenamide+emtricitabine+dolutegravir regimen.No significant differences in the incidence of adverse events were observed among the different regimens.Conclusion The the tenofovir alafenamide+emtricitabine+dolutegravir and tenofovir disoproxil fumarate+emtricitabine/lamivudine+rilpiv-irine regimens demonstrated relatively better efficacy and safety,potentially offering reliable long-term antivi-ral treatment options for acquired immune deficiency syndrome patients.